Humane Genomics
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading e
Y Combinator
yc-company-directory #1896Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading e
sourceHumane Genomics is classified as Developer tools from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Humane Genomics
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Authy
match 53Authy provides strong authentication for the connected world, protecting people and the enterprise against malicious attacks. Our two-factor authentication (2FA) security solution enables organizations to minimize risk while enhancing the user experience. Authy 2FA provides a fast-to-implement, highly scalable and proven 99.999 % reliable alternative to passwords. Used by 11,000+ websites serving 2 million consumers worldwide, it's designed to give users the ability to self-service or easily man
shared extracted concept terms: factor, authentication; shared product terms: design, highly, factor, authentication; shared affiliation: Y Combinator
Arpeggio Bio
match 51Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
shared extracted concept terms: rna; shared product terms: develop, target, factor, rna; shared affiliation: Y Combinator
Kernal Biologics
match 46Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boastin
shared extracted concept terms: selective; shared product terms: cancer, selective, target, off; same category: Developer tools; shared affiliation: Y Combinator
WhiteLab Genomics
match 41We have developed an AI platform enabling to accelerate the discovery and the design of genomic therapies such as Cell Therapies, RNA Therapies and DNA Therapies.
shared product terms: genomic, develop, design, therapie; shared affiliation: Y Combinator
Kopra Bio
match 41Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
shared product terms: develop, engineer, cancer, kill; shared affiliation: Y Combinator
Adventris Pharmaceuticals
match 33Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
shared product terms: cancer, target, off, approach; shared affiliation: Y Combinator